Ultragenyx Says Phase 3 Study on Rare Neurogenetic Disorder Missed Primary, Secondary Endpoints; Shares Fall After-Hours
Phase 3negativeNegative
AI Analysis
Summary
Ultragenyx Pharmaceutical reported that its Phase 3 study for a rare neurogenetic disorder failed to meet primary and secondary endpoints, resulting in a significant after-hours stock decline.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
missed primary and secondary endpoints
Importance:8/10
Sentiment:
-0.90
Phase 3 failurerare diseaseneurogenetic disorderprimary endpoint missedsecondary endpoint missed
Related Companies
Read the original article
Published by yahoo_finance on September 2, 2026 9:20 PM